MARKET

CHRS

CHRS

Coherus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.39
+0.15
+1.05%
After Hours: 14.39 0 0.00% 17:14 04/16 EDT
OPEN
14.26
PREV CLOSE
14.24
HIGH
14.51
LOW
14.12
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
22.22
52 WEEK LOW
13.53
MARKET CAP
1.05B
P/E (TTM)
8.93
1D
5D
1M
3M
1Y
5Y
Neutropenia Drugs Market Research Report by Product, by Material, by Technique, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19
Apr 14, 2021 (Heraldkeepers) -- The decrease in neutrophil production will cause Neutropenia. Neutrophils are a significant kind of white platelet,...
Heraldkeepers · 3d ago
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 3d ago
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 4d ago
Neutropenia Drugs Market May See a Big Move : Major Giants Richter Gedeon, Apotex, Biogenomics, Sandoz
Apr 10, 2021 (Market Insight Reports) -- Neutropenia Drugs Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition...
Market Insight Reports · 04/10 12:31
Polyarticular Juvenile Idiopathic Arthritis Drug Market 2021 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2027
Apr 08, 2021 (Market Stats News via COMTEX) -- The latest report as Polyarticular Juvenile Idiopathic Arthritis Drug Market acknowledges Size, Application...
Market Stats News · 04/08 18:46
Polyarticular Juvenile Idiopathic Arthritis Drug Market Segmentation and Forecasts 2020 - 2027 By Ameco Research
Comserve · 04/08 05:14
The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 5)
Benzinga · 04/06 12:04
Global Behcet Disease Drug Market Trend Survey 2021-2027 with Top Countries Data Industry Growth, Size, Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions Analysis Research Report | With Covid-19 Analysis
Apr 05, 2021 (The Expresswire) -- Global “Behcet Disease Drug Market” research report (2021-2027) covers the market outline and topographical districts with...
The Express Wire · 04/05 05:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CHRS. Analyze the recent business situations of Coherus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CHRS stock price target is 27.63 with a high estimate of 35.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 299
Institutional Holdings: 99.39M
% Owned: 135.96%
Shares Outstanding: 73.11M
TypeInstitutionsShares
Increased
68
6.38M
New
24
3.12M
Decreased
70
6.77M
Sold Out
27
1.49M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dennis Lanfear
Chief Financial Officer
Jean-Frederic Viret
Chief Operating Officer
Vincent Anicetti
Chief Technology Officer
.. ..
Chief Scientific Officer
Vladimir Vexler
Other
Thomas Fitzpatrick
Lead Director/Independent Director
Mats Wahlstrom
Director
Alan Mendelson
Director
Mark Stolper
Director
Kimberly Tzoumakas
Independent Director
James Healy
Independent Director
V. Bryan Lawlis
Independent Director
Samuel Nussbaum
Independent Director
Ali Satvat
Independent Director
Mary Szela
No Data
  • All
  • Financials
  • Insiders
More
About CHRS
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Webull offers kinds of Coherus Biosciences Inc stock information, including NASDAQ:CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.